From: Interstitial lung disease in patients with scleroderma - Treatment with rituximab
Pat.1. Pre-RTX | Pat.1. Post-RTX | Pat.2. Pre-RTX | Pat.2. Post-RTX | Pat. 3. Pre-RTX | Pat.3. Post-RTX | |
---|---|---|---|---|---|---|
Vital Cap (L) | 1.94 (65.2%) | 2.02 (68.5%) | 1.08 (44.8%) | 1.15 (48.3%) | 1.43 (53.4%) | 1.51 (56.7%) |
FEV 1 | 1.75 (68.6%) | 1.81 (71.6%) | 1.08 (53.1%) | 1.09 (54.5%) | 1.12 (49.2%) | 1.18 (52.2%) |
FEV1/VC | 90.35 | 89.69 | 99.91 | 94.86 | 78.38 | 78.15 |
TLCOc/VA (mol/min/Kpa) | 1.20 (68%) | 1.03 (59.2%) | 0.93 (54.8%) | 1.02 (60.6%) | 1.20 (68.0%) | 1.29 (73,8%) |
PCO2 (mmHg) | 44.1 | 42.8 | 32.6 | 40.2 | 33 | 35.1 |
PO2 (mmHg) | 83 | 86 | 84 | 92 | 64 | 75 |
Sat O2 (%) | 94.2 | 96.6 | 96.7 | 97.4 | 94.4 | 96.3 |